Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of a recombinant RSV vaccine (CHO cells) in adults
CTR20243803Phase 2Active
- Sponsor
- Chengdu Huarenkang Biotechnology
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus disease (RSV), sponsored by Chengdu Huarenkang Biotechnology. Started Nov 2024; status: active.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20243803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243803.